[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"portosystemic-shunt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:portosystemic-shunt":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100629992","portosystemic-shunt-associated-pulmonary-hypertension-multi-center-prospective-cohort-study-100629992",false,"NCT07481877","Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Diagnosis of Portosystemic Shunts:Imaging evidence suggestive of portosystemic shunts (congenital or acquired) or unequivocal clinical signs of portal hypertension (e.g., splenomegaly, varices).\n3. Diagnosis of Pulmonary Hypertension (PH):\n\n   * Confirmed by Right Heart Catheterization (RHC): mPAP \\> 20 mmHg; OR\n   * Highly suspected by Echocardiography: Peak TRV \\> 3.4 m\u002Fs or compliant with ESC\u002FERS guidelines for high probability of PH (Note: RHC is encouraged for all enrolled patients).\n4. Signed informed consent and willingness to strictly adhere to the follow-up schedule.\n\nExclusion Criteria:\n\n1. PH caused by other reasons\n2. Hepatocellular carcinoma (HCC) exceeding the Milan criteria.\n3. Active extrahepatic malignancy.\n4. Transjugular intrahepatic portosystemic shunt (TIPS) placement within the previous month.\n5. Pregnancy or lactation.\n6. Participation in other interventional clinical trials (drug or device) within the last 3 months.","ALL","18 Years",{"count":18,"type":19},300,"ESTIMATED","OBSERVATIONAL","This study aims to establish a multi-center registry cohort of portosystemic shunt-associated pulmonary hypertension, with the goal of clarifying the epidemiology, clinical features, phenotypic classification, response to targeted therapy, and prognostic outcomes in patients with portosystemic shunt-associated pulmonary hypertension.",[23,24],"Portosystemic Shunt","Pulmonary Hypertension",[23,24,26,27,28],"POPH","Portal hypertension","Cirrhosis","NOT_YET_RECRUITING","2026-03-13",{"date":32,"type":33},"2026-03-19","ACTUAL",{"date":35,"type":19},"2026-04-01",{"date":37,"type":19},"2031-04-01",{"name":39,"class":40},"Chinese Pulmonary Vascular Disease Research Group","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100525519","preemptive-tips-for-gastric-variceal-bleeding-in-patients-with-cirrhosis-100525519","NCT06122792","Preemptive TIPS for Gastric Variceal Bleeding in Patients With Cirrhosis","Preemptive Transjugular Intrahepatic Portosystemic Shunt for Gastric Variceal Bleeding in Patients With Cirrhosis: A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy);\n* Admission due to acute bleeding from gastric varices (IGV1 or GOV2).\n\nExclusion Criteria:\n\n* Prior treatment with TIPS or surgical shunt;\n* Presence of contraindications to endoscopic treatment, carvedilol, or TIPS;\n* Presence of hepatocellular carcinoma exceeding Milan criteria;\n* Presence of other systemic malignant tumors with expected survival time not exceeding 6 months;\n* Presence of uncontrollable infection or sepsis;\n* Presence of cardiac, pulmonary, or renal failure;\n* Pregnant or lactating women;\n* Refusal to sign the informed consent form.","75 Years",{"count":50,"type":19},144,"INTERVENTIONAL",[53],"NA","The prevalence of gastric varices is approximately 20%. It is important to note that gastric varices tend to bleed more severely, have a higher morbidity and mortality rate, and have a 35% to 90% risk of rebleeding after the cessation of acute hemorrhage. Because of the relatively low prevalence of gastric varices, the existing clinical studies have many deficiencies, and there is much controversy in the academic community, the optimal treatment and prevention strategies for gastric varices have not yet been fully defined.\n\nIn the last few years, important advances have been made in the treatment and prevention of gastric variceal bleeding in patients with cirrhosis. Experts agree that the combination of pharmacological and endoscopic injection of tissue adhesives should be the first line of therapy in the acute bleeding episode from isolated gastric varices (IGV1) or type 2 gastroesophageal varices (GOV2) varices; whereas transjugular intrahepatic portosystemic shunt (TIPS) is considered a rescue therapy. TIPS has been shown to effectively prevent variceal rebleeding but with a potential increase in the incidence of hepatic encephalopathy and\u002For liver failure. In this sense, a recent randomized controlled trial (RCT) in fundal variceal bleeding showed that an early TIPS, performed during the first 5 days after patient admission resulted in a significant decrease in failure to control bleeding and early and late rebleeding. However, the study was conducted for 4 years and only included 25 patients. Due to insufficient sample size, it was unable to reflect whether priority TIPS can bring survival benefits to patients with gastric variceal bleeding. Therefore, there is an urgent need for multi-center clinical studies with large samples to provide high-quality evidence in the field of prioritizing TIPS for the treatment of acute gastric variceal bleeding.\n\nThe present study aims to compare the preemptive TIPS (performed during the first 72 hours after endoscopy) with standard second prophylaxis (endoscopic injection of tissue adhesives plus carvedilol) for patients with acute bleeding from gastric varices (IGV1 or GOV2). The primary outcome will be a 6-week mortality from inclusion.",[56,57,23],"Portal Hypertension","Gastric Varices Bleeding","2023-11-03",{"date":60,"type":33},"2023-11-08",{"date":62,"type":19},"2024-01",{"date":64,"type":19},"2026-12",{"name":66,"class":40},"West China Hospital",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":48,"enrollmentInfo":74,"targetDuration":4,"studyType":51,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":83,"leadSponsor":84,"locationsCount":85},"100525516","preemptive-tips-for-variceal-bleeding-in-cirrhotic-patients-with-occlusive-portal-vein-thrombosis-100525516","NCT06122753","Preemptive TIPS for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis","Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Bleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT): A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Cirrhosis (diagnosed by imaging, laboratory tests, clinical symptoms, or liver biopsy);\n* Admission due to acute bleeding from esophagogastric varices;\n* Thrombus in the main trunk of the portal vein occupying ≥50% of the lumen.\n\nExclusion Criteria:\n\n* Prior treatment with TIPS or surgical shunt;\n* Presence of contraindications to endoscopic treatment, carvedilol, or TIPS;\n* Presence of hepatocellular carcinoma exceeding Milan criteria;\n* Presence of other systemic malignant tumors with expected survival time not exceeding 6 months;\n* Presence of uncontrollable infection or sepsis;\n* Presence of cardiac, pulmonary, or renal failure;\n* Pregnant or lactating women;\n* Refusal to sign the informed consent form.",{"count":75,"type":19},120,[53],"Portal vein thrombosis (PVT) can lead to a further increase in portal venous pressure and increase the risk of rebleeding. Whether patients with acute esophagogastric variceal bleeding with occlusive PVT benefit from preemptive TIPS is still controversial. The present study is directed at comparing the outcome of patients with acute variceal bleeding with occlusive PVT treated by standard therapy (vasoactive drugs + endoscopic variceal ligation) with or without preemptive TIPS (performed during the first 1-3 days after endoscopic procedure). The primary outcome is survival free of variceal rebleeding at 6 weeks from inclusion.",[56,79,80,23],"Portal Vein Thrombosis","Esophageal Varix Bleeding",{"date":60,"type":33},{"date":62,"type":19},{"date":64,"type":19},{"name":66,"class":40},1]